Jianglong P. Xu

Baoding, 071000, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Exosomal circ_0050688 Shapes a Chemoresistant Microenvironment by Driving Spatial Resistance Spreading in Glioblastoma via the MDM2 Pathway.

Exosomal circ_0050688 Shapes a Chemoresistant Microenvironment by Driving Spatial Resistance Spreading in Glioblastoma via the MDM2 Pathway.

Journal: Biomolecules
Published: April 19, 2026

Intercellular transfer of circ_0017636 via exosomal vehicles overcomes glioblastoma chemoresistance through ARRB1-mediated signaling restoration.

Intercellular transfer of circ_0017636 via exosomal vehicles overcomes glioblastoma chemoresistance through ARRB1-mediated signaling restoration.

Journal: Cellular signalling
Published: December 20, 2025

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.

Comprehensive understanding of glioblastoma molecular phenotypes: classification, characteristics, and transition.

Journal: Cancer biology & medicine
Published: May 07, 2024

CuO nanoparticles for glioma treatment in vitro and in vivo.

CuO nanoparticles for glioma treatment in vitro and in vivo.

Journal: Scientific reports
Published: January 25, 2024

EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.

EPIC-0307-mediated selective disruption of PRADX-EZH2 interaction and enhancement of temozolomide sensitivity to glioblastoma via inhibiting DNA repair and MGMT.

Journal: Neuro-oncology
Published: June 06, 2023

Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.

Exosomal circWDR62 promotes temozolomide resistance and malignant progression through regulation of the miR-370-3p/MGMT axis in glioma.

Journal: Cell death & disease
Published: April 22, 2022

lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy.

lncRNA PRADX is a Mesenchymal Glioblastoma Biomarker for Cellular Metabolism Targeted Therapy.

Journal: Frontiers in oncology
Published: March 03, 2022

RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).

RUNX1 (RUNX family transcription factor 1), a target of microRNA miR-128-3p, promotes temozolomide resistance in glioblastoma multiform by upregulating multidrug resistance-associated protein 1 (MRP1).

Journal: Bioengineered
Published: December 13, 2021

Identification and characterization of N6-methyladenosine modification of circRNAs in glioblastoma.

Identification and characterization of N6-methyladenosine modification of circRNAs in glioblastoma.

Journal: Journal of cellular and molecular medicine
Published: March 19, 2021

m6A modification in RNA: biogenesis, functions and roles in gliomas.

m6A modification in RNA: biogenesis, functions and roles in gliomas.

Journal: Journal of experimental & clinical cancer research : CR
Published: July 29, 2020

New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.

New understanding of the damage of SARS-CoV-2 infection outside the respiratory system.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: April 03, 2020

Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.

Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis.

Journal: Cancer biology & medicine
Published: January 08, 2020
Showing 1-12 of 14

Last Updated: 09/26/2026